<DOC>
	<DOCNO>NCT02697136</DOCNO>
	<brief_summary>The purpose study assess impact 29 intravenous infusion CER-001 vs. placebo , give weekly ( 9 infusion ) biweekly ( 20 infusion ) interval carotid vessel wall area measure 3TMRI , administer patient familial primary hypoalphalipoproteinemia proven CVD appropriate background lipid-lowering therapy .</brief_summary>
	<brief_title>CER-001 Therapy Novel Approach Treat Genetic Orphan Diseases</brief_title>
	<detailed_description>Subjects require acceptable baseline 3TMRI image carotid artery . Subjects meet eligibility criterion randomize receive CER-001 placebo ( 2:1 randomization scheme ) . Randomized subject return weekly total 9 infusion biweekly additional 20 infusion . 3TMRI image carotid femoral artery perform Week 8 , Week 24 ( primary endpoint ) Week 48 . The total study duration randomization range 50 54 week patient complete study design .</detailed_description>
	<mesh_term>Hypoalphalipoproteinemias</mesh_term>
	<criteria>Main Male female patient , age 18 . ApoAI &lt; 70 mg/dL Symptomatic asymptomatic cardiovascular disease Diagnosis genetically confirm HDLc deficiency due defect gene cod ABCA1 and/or ApoA1 Stable dose lipid lower therapy least 6 week prior baseline procedure Main Females childbearing potential Patients LCAT mutation Patients experience recent cardiovascular cerebrovascular event Hypertriglyceridemia ( &gt; 500 mg/dL ) Severe anemia ( Hgb &lt; 10 g/dL ) Uncontrolled diabetes ( HbA1c &gt; 10 % ) Congestive heart failure ( NYHA class II high ) Contraindication MRI scanning ( e.g. , implanted metal object , claustrophobia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Low HDL</keyword>
	<keyword>Low apoA-I</keyword>
	<keyword>ABCA-1 mutation</keyword>
	<keyword>ApoA-I mutation</keyword>
</DOC>